relapsing remitting multiple sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
FDA approved drug (Rapamycin) administrated to the patients, 2 mg daily for 6 months.
Treatment - Drugs
FDA approved drug (Rapamycin) administrated to the patients, 2 mg daily for 6 months
Sponsors
Vice-chancellor of Research and Technology, Isfahan University of Medical Sciences, Isfahan, Iran
Charity
The researcher
Eligibility
Sex/Gender
All
Age
24 Years to 27 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Relapsing- Remitting MS; MRI records that proved the existence of demyelination; 0-6 expanded disability status scale (EDSS); lack of response to ß interferon or glatiramer acetate; stopping ß interferon or glatiramer acetate one month before the experimentation . Exclusion criteria: primary progressive MS; history of immunosuppressive therapy; side effects of the drug; steroid therapy in the last one month; any sign of infection and cancer; cardiovascular and hematological disorders; high serum cholesterol and using medication for it; history of hepatic cirrhosis or other liver diseases that require treatment; history of C and B hepatitis; active CMV infection; renal diseases which require treatment; active lung diseases, diabetes, hyperthyroidism, infection with HIV, tuberculosis; history of alcohol misuse during last 6 months; phobia from MRI (claustrophobia) and pregnant and lactating women.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in plaque area and number, variation in the expesion of FOXP3 gene. Timepoint: Before and 6 months after the therapy with rapamyin. Method of measurement: MRI, real-time PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Th1, 2 and 17 Cytokine variation. Timepoint: Before and 6 months after therapy with rapamycin. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMansour Salehi
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Scie
Outcome results
None listed